Author:
Gbary-Lagaud Eléonore,Houphouet-Mwandji Carine,Effoh Denis,Adjoby Roland
Abstract
Objective: To evaluate the surgical management of myomas at the Teaching Hospital of Angré according to the FIGO (International Federation of Gynecology and Obstetrics) classification. Patients and methods: This was a cross-sectional study at the Teaching Hospital of Angre from January 1, 2020, to December 31, 2022. Patients whose operative indication was clearly identified were included in the study. Incomplete files were not included. The variables studied were anthropometric parameters, clinical characteristics of myomas, and surgery. Due to the large size and multifocal location of uterine myomas, the therapeutic option remained surgery by laparotomy. Results: Most patients were over 35 years old (71.5%) and nulliparous (52.8%). The first indication for surgery was menometrorrhagia (88.6%), followed by the desire for motherhood (37.8%) and dysmenorrhoea (20.2%) for myomas most often FIGO type 4 (p = 0.0031). Myomectomy under cervical-isthmic tourniquet was the most common procedure for FIGO type 4 myomas (66.1%; p = 0.0543). Hysterectomy was most frequently performed for FIGO type 7 myomas (43.9%; p = 0.0543). For myomectomy, the first complication was anaemia (3.5%) followed by uterine suture haemorrhage (1.7%) (p = 0.5139). Conclusion: Our surgical practice at the Teaching Hospital of Angre is in accordance with FIGO recommendations. However, an effort should be made to promote the minimally invasive surgical approach (laparoscopic, hysteroscopic, transvaginal ablation) for small fibroids (≤ 5 cm) or FIGO type 0 to 3, which is not very frequent in our current practice.
Publisher
Heighten Science Publications Corporation
Reference41 articles.
1. 1. Fernandez H, Chabbert Buffet N, Allouche S. Prévalence du fibrome utérin en France et impact sur la qualité de vie à partir d'une enquête menée auprès de 2500 femmes de 30-55ans [Prevalence of uterine fibroids in France and impact on quality of life: results of a survey among 2500 women between 30-55 years]. J Gynecol Obstet Biol Reprod (Paris). 2014 Nov;43(9):721-7. French. doi: 10.1016/j.jgyn.2014.07.006. Epub 2014 Aug 11. PMID: 25124196.
2. 2. Lansac J, Lecomte P, Marret H. Gynecology for the practitioner. Elsevier Masson SAS. 2012; 8: 65-80.
3. 3. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003 Jan;188(1):100-7. doi: 10.1067/mob.2003.99. PMID: 12548202.
4. 4. Okogbo FO, Ezechi OC, Loto OM, Ezeobi PM. Uterine Leiomyomata in South Western Nigeria: a clinical study of presentations and management outcome. Afr Health Sci. 2011 Jun;11(2):271-8. PMID: 21857861; PMCID: PMC3158515.
5. 5. Racinet C. Epidemiology, risk factors and symptomatology of uterine myomas. MT Reproductive Medicine Gynecology Endocrinology. 2009; 11, 2: 118-122.